DSGN
Design Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.64
+3.20%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | 537.0K | 466.0K |
| Gross Profit | — | — | — | (537.0K) | (466.0K) |
| Operating Expenses | |||||
| R&D Expense | 58.8M | 59.1M | 44.4M | 57.1M | 48.6M |
| SG&A Expense | 20.6M | 20.3M | 18.0M | 21.1M | 19.0M |
| General & Admin Expense | 20.6M | 20.3M | 18.0M | 21.1M | 19.0M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | (537.0K) | (466.0K) |
| Total Operating Expenses | 79.4M | 79.5M | 62.4M | 77.7M | 67.1M |
| Cost and Expenses | 79.4M | 79.5M | 62.4M | 78.2M | 67.6M |
| Operating Income (EBIT) | (79.4M) | (79.5M) | (62.4M) | (78.2M) | (67.6M) |
| Non-Operating | |||||
| Interest Income | 8.6M | 9.7M | 12.8M | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 8.6M | 9.7M | 12.8M | — | — |
| Other Non-Op Income/Expense | 8.6M | 9.7M | 12.8M | 11.3M | 4.3M |
| Non-Operating Income (excl Interest) | (6.6M) | (9.7M) | (12.8M) | (11.3M) | (4.3M) |
| EBT (Pre-Tax Income) | (70.8M) | (69.8M) | (49.6M) | (66.9M) | (63.3M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (70.8M) | (69.8M) | (49.6M) | (66.9M) | (63.3M) |
| Earnings from Cont. Ops | (70.8M) | (69.8M) | (49.6M) | (66.9M) | (63.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (70.8M) | (69.8M) | (49.6M) | (66.9M) | (63.3M) |
| Per Share | |||||
| Basic EPS | ($1.18) | ($1.22) | ($0.88) | ($1.19) | ($1.14) |
| Diluted EPS | ($1.18) | ($1.22) | ($0.88) | ($1.19) | ($1.14) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 62.5M | 57.3M | 56.6M | 56.0M | 55.7M |
| Diluted Shares Outstanding | 62.5M | 57.3M | 56.6M | 56.0M | 55.7M |
| Profitability Metrics | |||||
| EBITDA | (72.2M) | (69.2M) | (49.0M) | (66.3M) | (62.9M) |
| D&A | 619.0K | 622.0K | 596.0K | 537.0K | 406.0K |
| EBIT | (72.8M) | (69.8M) | (49.6M) | (66.9M) | (63.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026